CEO Update: December 2020
Insitu Biologics had several key accomplishments in 2020, setting the stage for an even better 2021. We significantly reduced our shareholders-of-record, renegotiated and renewed our license agreement with LifeCore Biomedical, and conducted successful bench and animal work on our new ropivacaine-based formulation.
For additional information regarding our progress, please take some time to read our company update.
Thank you and best wishes for a fantastic 2021!